BLAS
GIL EXTREMERA
Investigador no período 2018-2019
Andrzej
Budaj
Publicacións nas que colabora con Andrzej Budaj (6)
2021
-
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
Journal of the American College of Cardiology, Vol. 78, Núm. 5, pp. 421-433
2019
-
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 8, pp. 618-628
2018
-
Alirocumab and cardiovascular outcomes after acute coronary syndrome
New England Journal of Medicine, Vol. 379, Núm. 22, pp. 2097-2107
2013
-
Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus
JAMA Internal Medicine, Vol. 173, Núm. 18, pp. 1682-1692
2008
-
Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial
The Lancet, Vol. 372, Núm. 9644, pp. 1174-1183
-
Telmisartan, ramipril, or both in patients at high risk for vascular events
New England Journal of Medicine, Vol. 358, Núm. 15, pp. 1547-1559